Case Western Reserve University https://case.edu and ICBM Medical Inc. signed a one year licensing agreement to commercially advance a low cost rapid catalytic biomarker technology to improve patient screening and monitoring for a range of clinical conditions.
ICBM Medical established last year and located in Cleveland near Case Western was founded to offer innovative point-of-use diagnostic medical devices to dramatically advance disease detection.
By leveraging existing biomarkers and developing new ones, ICBM Medical plans to commercialize their first clinical product applications while establishing a pipeline for future biosensors to outperform current tests more quickly and at a lower cost.
Taipei Medical University (TMU) www.tmu.edu.tw in Taiwan has been an active partner and collaborator with Case Western and now is active with ICBM Medical. In addition to ongoing-in-kind clinical testing of the biosensors, TMU is investing $500,000 in ICBM Medical.
Recently both Case Western and ICBM Medical were notified that the Ohio Third Frontier www.ohiothirdfrontier.com Technology Validation and Start-up fund will provide $150,000 to help advance the detection technology from the lab to commercial markets.